# US 2003/0077683 A1 · IKK-alpha proteins, nucleic acids and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077683 A1
- Document ID: US20030077683A1
- Status: Published application
- Kind: A1
- Application number: 10/243,408
- Filed: 2002-09-13
- Published: 2003-04-24
- Earliest claimed: 1997-07-01
- Assignees: Amgen Inc.
- Inventors: Mike Rothe; Zhaodan Cao; Catherine Regnier
- Web page: https://patentgrep.com/patent/US20030077683A1

## CPC

- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides methods and compositions relating to an IκB kinase, IKK-α, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-α encoding nucleic acids or purified from human cells. The invention provides isolated IKK-α hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-α genes, IKK-α-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

## Claims

### Claim 1

An isolated IKK-αGlu543 polypeptide, comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:4, which consecutive amino acid residues comprise the amino acid residue 543 (Glu) of SEQ ID NO:4.

### Claim 2 (depends on 1)

An isolated polypeptide according to claim 1, wherein said polypeptide has an activity selected from at least one of: a kinase or kinase inhibitory activity, a NIK-binding or binding inhibitory activity, an IκB-binding or binding inhibitory activity and an NFκB activating or inhibitory activity.

### Claim 3

An isolated or recombinant IKK-αA1628 nucleic acid comprising at least 24 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:3, which consecutive polynucleotides comprise the polynucleotide 1628 (A) of SEQ ID NO:3.

### Claim 4 (depends on 1)

A recombinant nucleic acid encoding a polypeptide according to claim 1.

### Claim 5 (depends on 4)

A cell comprising a nucleic acid according to claim 4.

### Claim 6 (depends on 1, 4)

A method of making an isolated polypeptide according to claim 1, said method comprising steps: introducing a nucleic acid according to claim 4 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is expressed as a translation product comprising said polypeptide, and isolating said translation product.

### Claim 7 (depends on 1)

A method of screening for an agent which modulates the interaction of an IKK polypeptide to a binding target, said method comprising the steps of:
incubating a mixture comprising:
an isolated polypeptide according to claim 1,
a binding target of said polypeptide, and
a candidate agent;
under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity;
detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.

### Claim 8 (depends on 7)

A method according to claim 7, wherein said binding target is a natural intracellular substrate and said reference and agent-biased binding affinity is detected as phosphorylation of said substrate.

### Claim 9

A method of screening for an agent which modulates the interaction of an IKK polypeptide to a binding target, said method comprising the steps of:
incubating a mixture comprising: an isolated polypeptide comprising SEQ ID NO: 2 or 4, or a deletion mutant thereof retaining IκB kinase activity, an IκB polypeptide comprising at least a six residue domain of a natural IκB comprising at least one of Ser32 and Ser 36, and a candidate agent;
under conditions whereby, but for the presence of said agent, said polypeptide specifically phosphorylates said IκB polypeptide at at least one of said Ser32 and Ser36 at a reference activity;
detecting the polypeptide-induced phosphorylation of said IκB polypeptide at at least one of said Ser32 and Ser36 to determine an agent-biased activity, wherein a difference between the agent-biased activity and the reference activity indicates that said agent modulates the ability of said polypeptide to specifically phosphorylate a IκB polypeptide.

### Claim 10

A method for modulating signal transduction involving IκB in a cell, said method comprising the step of modulating IKK-α (SEQ ID NO:4) kinase activity.

### Claim 11 (depends on 10)

The method of claim 10, wherein said modulating step comprises contacting the cell with a serine/threonine kinase inhibitor.
